Comparison of subretinal versus intravitreal injection of tissue type plasminogen activator combined with conbercept and C3F8 in the treatment of acute macular hemorrhage
Phase 4
Recruiting
- Conditions
- submacular hemorrhage
- Registration Number
- ChiCTR2400089058
- Lead Sponsor
- Dongguan Guangming Ophthalmology Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Age above 45 years old;<br>2. SMH with a duration of no more than 2 weeks from onset to surgery;<br>3. Diagnosed as wAMD or PCV based on fundus photography, FFA combined with ICGA examination;<br>4. The thickness of subretinal hemorrhage involving the macular fovea is greater than 125um (SD-OCT scan), and the diameter exceeds 1PD size.
Exclusion Criteria
- Subretinal hemorrhage in the macular area caused by factors other than dehumidifying age-related macular degeneration and PCV;<br>2. Individuals with a history of cerebral infarction, cerebral ischemia, or myocardial infarction within 6 months;<br>3. Those who have had previous vitrectomy surgery or macular degeneration causing scars;<br>4. Patients who use anticoagulants;<br>5. People with diabetes retinopathy, uveitis and high myopia;<br>6. Those who cannot maintain a face down position;<br>7. Patients with refractive interstitial opacity that affects fundus observation.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Displacement and absorption of SMH;visual acuity;central PED thickness;Central retinal thickness;Intraocular pressure;
- Secondary Outcome Measures
Name Time Method